Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications

被引：138

作者：

Guillemette, C. ^{[1
,2
]}

Levesque, E. ^{[1
,2
]}

Rouleau, M. ^{[1
,2
]}

机构：

[1] CHU, Quebec Res Ctr, Pharmacogen Lab, Quebec City, PQ, Canada

[2] Univ Laval, Fac Pharm, Quebec City, PQ, Canada

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 96卷 / 03期

基金：

加拿大健康研究院; 加拿大自然科学与工程研究理事会;

关键词：

COPY-NUMBER-VARIATION; UDP-GLUCURONOSYLTRANSFERASES; COLORECTAL-CANCER; GLUCURONIDATION ACTIVITY; DELETION POLYMORPHISMS; GENETIC POLYMORPHISMS; PROTEIN EXPRESSION; DNA METHYLATION; PROSTATE-CANCER; SPLICE VARIANTS;

D O I：

10.1038/clpt.2014.126

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Glucuronidation by uridine diphospho-glucurbnosyltransferase enzymes (UGTs) is a major phase II biotransformation pathway and, complementary to phase I metabolism and membrane transport, one of the most important cellular defense mechanisms responsible for the inactivation of therapeutic drugs, other xenobiotics, and endogenous molecules. Interindividual variability in UGT pathways is significant and may have profound pharmacological and toxicological implications. Several genetic and genomic processes underlie this variability and are discussed in relation to drug metabolism and diseases such as cancer.

引用

页码：324 / 339

页数：16

共 82 条

[1] The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk [J].

Angstadt, Andrea Y. ;

Berg, Arthur ;

Zhu, Junjia ;

Miller, Paige ;

Hartman, Terryl J. ;

Lesko, Samuel M. ;

Muscat, Joshua E. ;

Lazarus, Philip ;

Gallagher, Carla J. .

CANCER, 2013, 119 (13) :2477-2485

[2] Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios [J].

Anielski, Patricia ;

Simmchen, Juliane ;

Wassill, Lars ;

Ganghofner, Dirk ;

Thieme, Detlef .

DRUG TESTING AND ANALYSIS, 2011, 3 (10) :645-651

[3] Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype [J].

Balliet, Renee M. ;

Chen, Gang ;

Gallagher, Carla J. ;

Dellinger, Ryan W. ;

Sun, Dongxiao ;

Lazarus, Philip .

CANCER RESEARCH, 2009, 69 (07) :2981-2989

[4] PharmGKB summary: very important pharmacogene information for UGT1A1 [J].

Barbarino, Julia M. ;

Haidar, Cyrine E. ;

Klein, Teri E. ;

Altman, Russ B. .

PHARMACOGENETICS AND GENOMICS, 2014, 24 (03) :177-183

[5] A decade of exploring the cancer epigenome - biological and translational implications [J].

Baylin, Stephen B. ;

Jones, Peter A. .

NATURE REVIEWS CANCER, 2011, 11 (10) :726-734

[6] Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells [J].

Belanger, Anne-Sophie ;

Tojcic, Jelena ;

Harvey, Mario ;

Guillemette, Chantal .

BMC MOLECULAR BIOLOGY, 2010, 11

[7] Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans [J].

Bellemare, Judith ;

Rouleau, Melanie ;

Harvey, Mario ;

Popa, Ion ;

Pelletier, Georges ;

Tetu, Bernard ;

Guillemette, Chantal .

JOURNAL OF PATHOLOGY, 2011, 223 (03) :425-435

[8] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].

Beutler, E ;

Gelbart, T ;

Demina, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174

[9] Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT [J].

Bigo, Cyril ;

Caron, Sarah ;

Dallaire-Theroux, Amelie ;

Barbier, Olivier .

DRUG METABOLISM REVIEWS, 2013, 45 (01) :34-47

[10] Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): Mechanisms responsible for interindividual variation of UGT levels [J].

Bock, Karl Walter .

BIOCHEMICAL PHARMACOLOGY, 2010, 80 (06) :771-777

← 1 2 3 4 5 6 7 8 9 →